<DOC>
	<DOCNO>NCT01381926</DOCNO>
	<brief_summary>The purpose study determine change bone turnover marker calcitonin follow initiation exenatide compare placebo postmenopausal woman wtih type 2 diabetes . Hypothesis 1a : Bone resorption ( measure osteocalcin bone-specific alkaline phosphatase ) low bone formation ( measure type I collagen crosslinked aminoterminal peptide urine ( Urine NTX ) ) high subject treat exenatide compare subject treat placebo . Hypothesis 1b : Calcitonin level vary significantly period treatment exenatide vs. placebo .</brief_summary>
	<brief_title>Changes Bone Turnover With Exposure GLP-1 Receptor Agonist</brief_title>
	<detailed_description>Patients Type 2 Diabetes Mellitus ( T2DM ) increase risk fracture , despite bone mineral density ( BMD ) level similar age sex match cohort . Recent study indicate change incretin ( INtestinal seCRETion INsulin ) hormones set T2DM may play role bone metabolism . Two incretin hormone , gastric inhibitory polypeptide ( GIP ) glucagon-like peptide-1 ( GLP-1 ) , show involved bone turnover regulation , addition effect increase insulin secretion decrease glucagon secretion glucose-dependent manner . In addition , rise glucagon-like peptide-2 ( GLP-2 ) postprandial state find direct effect reduce bone resorption non-fasting state treatment GLP-2 improve BMD postmenopausal woman . Due glucose lower effect , incretin hormone therapeutic target treatment T2DM GLP-1 receptor agonist ( i.e . exenatide ) inhibition incretin hormone metabolism via dipeptidyl peptidase 4 ( DPP-4 ) inhibitor . The GLP-1 receptor analog exenatide lead approximate 13-fold increase GLP-1 effect compare approximate double incretin hormone level current DDP-4 inhibitor . In rodent model , calcitonin level rise significantly follow treatment GLP-1 receptor agonist , lead c-cell hyperplasia . However , review calcitonin change human cynomolgus monkey treat GLP-1 receptor agonist show similar result .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Exenatide</mesh_term>
	<criteria>Postmenopausal woman ( defined age ≥45 year old amenorrhea &gt; 2years ) Type 2 DM currently diabetesspecific medication ( ) treat monotherapy metformin sulfonylurea . Patients treat insulin monotherapy also eligible total daily dose insulin ≤10units . If medication diabetes prior study entry , medication discontinue 2 week prior study initiation . Hemoglobin A1c ( HbA1c ) 6.59.0 % Use incretin mimetic ( i.e . exenatide , liraglutide ) , DPP4 inhibitor ( i.e . sitagliptin , saxagliptin ) , thiazolidinedione , oral glucocorticoid 6 month prior study eligible Known osteoporosis patient treat osteoporosisspecific medication ( bisphosphonate , teriparatide ) estrogen ( include Selective Estrogen Receptor Modulators ( SERMs ) ) anticipate imminent treatment one medication exclude study Chronic kidney disease ( calculate GFR &lt; 30 ml/min ) disease know affect bone turnover ( i.e . Paget Disease , Osteogenesis Imperfecta , HIV ) exclude study . History pancreatitis</criteria>
	<gender>Female</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Type 2 diabetes , exenatide , Byetta</keyword>
</DOC>